New York 2025 Session Status: Introduced

S6758 — Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

Last action — In Assembly Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed Assembly
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Senate. Introduced March 24, 2025. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Prognosis

Not enough signal yet

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

The bill requires discussions of risks between practitioners and patients prescribed certain controlled substances.

This bill mandates that healthcare practitioners must discuss specific risks with patients when prescribing schedule II controlled substances or opioid analgesics. Additionally, it requires the department of health to create guidelines for these discussions.

What this means for you
  • Healthcare: Practitioners will be required to discuss specific risks with patients when prescribing certain medications.

Summary

Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Bill Text

Action History

  1. REFERRED TO HEALTH

  2. DELIVERED TO ASSEMBLY

  3. PASSED SENATE

  4. ADVANCED TO THIRD READING

  5. 2ND REPORT CAL.

  6. 1ST REPORT CAL.1095

  7. PRINT NUMBER 6758B

  8. AMEND AND RECOMMIT TO HEALTH

  9. PRINT NUMBER 6758A

  10. AMEND AND RECOMMIT TO HEALTH

  11. REFERRED TO HEALTH

  12. REFERRED TO HEALTH

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S6758 do?
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Who sponsors S6758?
S6758 is sponsored by Nathalia Fernandez.
What is the current status of S6758?
This bill has been introduced in the Senate. Introduced March 24, 2025. It must pass committee before a floor vote.
Where can I track S6758?
Track S6758 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S6758

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S6758

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →